Abstract
Summary
According to our LPI (LP Information) latest study, the global Inactivated Vaccine market size was valued at US$ 5688.3 million in 2023. With growing demand in downstream market, the Inactivated Vaccine is forecast to a readjusted size of US$ 7199.6 million by 2030 with a CAGR of 3.4% during review period.
The research report highlights the growth potential of the global Inactivated Vaccine market. Inactivated Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Inactivated Vaccine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Inactivated Vaccine market.
Inactivated vaccines are viruses or bacteria that are first cultured and then inactivated with heat or chemicals. Inactivated vaccines may consist of whole viruses or bacteria, or they may consist of fragments that cleave together to form a cleaved vaccine.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Inactivated Vaccine market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Inactivated Vaccine market. It may include historical data, market segmentation by Type (e.g., Children Inactivated Vaccine, Adult Inactivated Vaccine), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Inactivated Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Inactivated Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Inactivated Vaccine industry. This include advancements in Inactivated Vaccine technology, Inactivated Vaccine new entrants, Inactivated Vaccine new investment, and other innovations that are shaping the future of Inactivated Vaccine.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Inactivated Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for Inactivated Vaccine product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Inactivated Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Inactivated Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Inactivated Vaccine market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Inactivated Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Inactivated Vaccine market.
Market Segmentation:
Inactivated Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Children Inactivated Vaccine
Adult Inactivated Vaccine
Segmentation by application
Hospital
Medical Center
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Astellas Pharma(Japan)
CSL Limited(Australia)
Emergent BioSolutions(U.S.)
GlaxoSmithKline(U.K.)
Johnson & Johnson(U.S.)
MedImmune(U.S.)
Merck & Co(U.S.)
Pfizer(U.S.)
Sanofi Pasteur(France)
Serum Institute of India Pvt(India)
The research report highlights the growth potential of the global Inactivated Vaccine market. Inactivated Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Inactivated Vaccine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Inactivated Vaccine market.
Inactivated vaccines are viruses or bacteria that are first cultured and then inactivated with heat or chemicals. Inactivated vaccines may consist of whole viruses or bacteria, or they may consist of fragments that cleave together to form a cleaved vaccine.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Inactivated Vaccine market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Inactivated Vaccine market. It may include historical data, market segmentation by Type (e.g., Children Inactivated Vaccine, Adult Inactivated Vaccine), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Inactivated Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Inactivated Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Inactivated Vaccine industry. This include advancements in Inactivated Vaccine technology, Inactivated Vaccine new entrants, Inactivated Vaccine new investment, and other innovations that are shaping the future of Inactivated Vaccine.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Inactivated Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for Inactivated Vaccine product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Inactivated Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Inactivated Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Inactivated Vaccine market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Inactivated Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Inactivated Vaccine market.
Market Segmentation:
Inactivated Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Children Inactivated Vaccine
Adult Inactivated Vaccine
Segmentation by application
Hospital
Medical Center
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Astellas Pharma(Japan)
CSL Limited(Australia)
Emergent BioSolutions(U.S.)
GlaxoSmithKline(U.K.)
Johnson & Johnson(U.S.)
MedImmune(U.S.)
Merck & Co(U.S.)
Pfizer(U.S.)
Sanofi Pasteur(France)
Serum Institute of India Pvt(India)
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Inactivated Vaccine Market Size 2019-2030
2.1.2 Inactivated Vaccine Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Inactivated Vaccine Segment by Type
2.2.1 Children Inactivated Vaccine
2.2.2 Adult Inactivated Vaccine
2.3 Inactivated Vaccine Market Size by Type
2.3.1 Inactivated Vaccine Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Inactivated Vaccine Market Size Market Share by Type (2019-2024)
2.4 Inactivated Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Medical Center
2.5 Inactivated Vaccine Market Size by Application
2.5.1 Inactivated Vaccine Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Inactivated Vaccine Market Size Market Share by Application (2019-2024)
3 Inactivated Vaccine Market Size by Player
3.1 Inactivated Vaccine Market Size Market Share by Players
3.1.1 Global Inactivated Vaccine Revenue by Players (2019-2024)
3.1.2 Global Inactivated Vaccine Revenue Market Share by Players (2019-2024)
3.2 Global Inactivated Vaccine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Inactivated Vaccine by Regions
4.1 Inactivated Vaccine Market Size by Regions (2019-2024)
4.2 Americas Inactivated Vaccine Market Size Growth (2019-2024)
4.3 APAC Inactivated Vaccine Market Size Growth (2019-2024)
4.4 Europe Inactivated Vaccine Market Size Growth (2019-2024)
4.5 Middle East & Africa Inactivated Vaccine Market Size Growth (2019-2024)
5 Americas
5.1 Americas Inactivated Vaccine Market Size by Country (2019-2024)
5.2 Americas Inactivated Vaccine Market Size by Type (2019-2024)
5.3 Americas Inactivated Vaccine Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Inactivated Vaccine Market Size by Region (2019-2024)
6.2 APAC Inactivated Vaccine Market Size by Type (2019-2024)
6.3 APAC Inactivated Vaccine Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Inactivated Vaccine by Country (2019-2024)
7.2 Europe Inactivated Vaccine Market Size by Type (2019-2024)
7.3 Europe Inactivated Vaccine Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Inactivated Vaccine by Region (2019-2024)
8.2 Middle East & Africa Inactivated Vaccine Market Size by Type (2019-2024)
8.3 Middle East & Africa Inactivated Vaccine Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Inactivated Vaccine Market Forecast
10.1 Global Inactivated Vaccine Forecast by Regions (2025-2030)
10.1.1 Global Inactivated Vaccine Forecast by Regions (2025-2030)
10.1.2 Americas Inactivated Vaccine Forecast
10.1.3 APAC Inactivated Vaccine Forecast
10.1.4 Europe Inactivated Vaccine Forecast
10.1.5 Middle East & Africa Inactivated Vaccine Forecast
10.2 Americas Inactivated Vaccine Forecast by Country (2025-2030)
10.2.1 United States Inactivated Vaccine Market Forecast
10.2.2 Canada Inactivated Vaccine Market Forecast
10.2.3 Mexico Inactivated Vaccine Market Forecast
10.2.4 Brazil Inactivated Vaccine Market Forecast
10.3 APAC Inactivated Vaccine Forecast by Region (2025-2030)
10.3.1 China Inactivated Vaccine Market Forecast
10.3.2 Japan Inactivated Vaccine Market Forecast
10.3.3 Korea Inactivated Vaccine Market Forecast
10.3.4 Southeast Asia Inactivated Vaccine Market Forecast
10.3.5 India Inactivated Vaccine Market Forecast
10.3.6 Australia Inactivated Vaccine Market Forecast
10.4 Europe Inactivated Vaccine Forecast by Country (2025-2030)
10.4.1 Germany Inactivated Vaccine Market Forecast
10.4.2 France Inactivated Vaccine Market Forecast
10.4.3 UK Inactivated Vaccine Market Forecast
10.4.4 Italy Inactivated Vaccine Market Forecast
10.4.5 Russia Inactivated Vaccine Market Forecast
10.5 Middle East & Africa Inactivated Vaccine Forecast by Region (2025-2030)
10.5.1 Egypt Inactivated Vaccine Market Forecast
10.5.2 South Africa Inactivated Vaccine Market Forecast
10.5.3 Israel Inactivated Vaccine Market Forecast
10.5.4 Turkey Inactivated Vaccine Market Forecast
10.5.5 GCC Countries Inactivated Vaccine Market Forecast
10.6 Global Inactivated Vaccine Forecast by Type (2025-2030)
10.7 Global Inactivated Vaccine Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Astellas Pharma(Japan)
11.1.1 Astellas Pharma(Japan) Company Information
11.1.2 Astellas Pharma(Japan) Inactivated Vaccine Product Offered
11.1.3 Astellas Pharma(Japan) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Astellas Pharma(Japan) Main Business Overview
11.1.5 Astellas Pharma(Japan) Latest Developments
11.2 CSL Limited(Australia)
11.2.1 CSL Limited(Australia) Company Information
11.2.2 CSL Limited(Australia) Inactivated Vaccine Product Offered
11.2.3 CSL Limited(Australia) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 CSL Limited(Australia) Main Business Overview
11.2.5 CSL Limited(Australia) Latest Developments
11.3 Emergent BioSolutions(U.S.)
11.3.1 Emergent BioSolutions(U.S.) Company Information
11.3.2 Emergent BioSolutions(U.S.) Inactivated Vaccine Product Offered
11.3.3 Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Emergent BioSolutions(U.S.) Main Business Overview
11.3.5 Emergent BioSolutions(U.S.) Latest Developments
11.4 GlaxoSmithKline(U.K.)
11.4.1 GlaxoSmithKline(U.K.) Company Information
11.4.2 GlaxoSmithKline(U.K.) Inactivated Vaccine Product Offered
11.4.3 GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 GlaxoSmithKline(U.K.) Main Business Overview
11.4.5 GlaxoSmithKline(U.K.) Latest Developments
11.5 Johnson & Johnson(U.S.)
11.5.1 Johnson & Johnson(U.S.) Company Information
11.5.2 Johnson & Johnson(U.S.) Inactivated Vaccine Product Offered
11.5.3 Johnson & Johnson(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Johnson & Johnson(U.S.) Main Business Overview
11.5.5 Johnson & Johnson(U.S.) Latest Developments
11.6 MedImmune(U.S.)
11.6.1 MedImmune(U.S.) Company Information
11.6.2 MedImmune(U.S.) Inactivated Vaccine Product Offered
11.6.3 MedImmune(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 MedImmune(U.S.) Main Business Overview
11.6.5 MedImmune(U.S.) Latest Developments
11.7 Merck & Co(U.S.)
11.7.1 Merck & Co(U.S.) Company Information
11.7.2 Merck & Co(U.S.) Inactivated Vaccine Product Offered
11.7.3 Merck & Co(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Merck & Co(U.S.) Main Business Overview
11.7.5 Merck & Co(U.S.) Latest Developments
11.8 Pfizer(U.S.)
11.8.1 Pfizer(U.S.) Company Information
11.8.2 Pfizer(U.S.) Inactivated Vaccine Product Offered
11.8.3 Pfizer(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Pfizer(U.S.) Main Business Overview
11.8.5 Pfizer(U.S.) Latest Developments
11.9 Sanofi Pasteur(France)
11.9.1 Sanofi Pasteur(France) Company Information
11.9.2 Sanofi Pasteur(France) Inactivated Vaccine Product Offered
11.9.3 Sanofi Pasteur(France) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Sanofi Pasteur(France) Main Business Overview
11.9.5 Sanofi Pasteur(France) Latest Developments
11.10 Serum Institute of India Pvt(India)
11.10.1 Serum Institute of India Pvt(India) Company Information
11.10.2 Serum Institute of India Pvt(India) Inactivated Vaccine Product Offered
11.10.3 Serum Institute of India Pvt(India) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Serum Institute of India Pvt(India) Main Business Overview
11.10.5 Serum Institute of India Pvt(India) Latest Developments
12 Research Findings and Conclusion